نتایج جستجو برای: tumorigenesis antiangiogenesis

تعداد نتایج: 25649  

Journal: :Molecular therapy : the journal of the American Society of Gene Therapy 2011
Jinlong Yin Jun-Kyum Kim Jai-Hee Moon Samuel Beck Dachuan Piao Xun Jin Sung-Hak Kim Young Chang Lim Do-Hyun Nam Seungkwon You Hyunggee Kim Yun-Jaie Choi

Glioma stem cells (GSCs) are known to be maintained within a "vascular niche"; thereby, disruption of this microenvironment using antiangiogenesis agents is a promising therapeutic modality. However, this regimen leads to treatment failure and tumor recurrence in patients with glioblastoma multiforme (GBM). Therefore, more effective therapeutic approaches that can eradicate GSCs and the bulk tu...

2017
Zhijie Wang Sarina Piha-Paul Filip Janku Vivek Subbiah Naiyi Shi Jing Gong Chetna Wathoo Kenna Shaw Kenneth Hess Russell Broaddus Aung Naing David Hong Apostolia M. Tsimberidou Daniel Karp James Yao Funda Meric-Bernstam Siqing Fu

PURPOSE Genetic alterations such as activating KRAS and/or inactivating TP53 are thought to be the most common drivers to tumorigenesis. Therefore, we assessed phase I cancer patients with KRAS+/TP53+ mutations. RESULTS Approximately 8% of patients referred to phase I clinical trials harbored concurrent KRAS and TP53 mutations. Patients who received a phase I trial therapy (n = 57) had a medi...

Journal: :Cancer research 2015
Shengliang Zhang Lanlan Zhou Bo Hong A Pieter J van den Heuvel Varun V Prabhu Noel A Warfel Christina Leah B Kline David T Dicker Levy Kopelovich Wafik S El-Deiry

The tumor-suppressor p53 prevents cancer development via initiating cell-cycle arrest, cell death, repair, or antiangiogenesis processes. Over 50% of human cancers harbor cancer-causing mutant p53. p53 mutations not only abrogate its tumor-suppressor function, but also endow mutant p53 with a gain of function (GOF), creating a proto-oncogene that contributes to tumorigenesis, tumor progression,...

Journal: :Mathematical and Computer Modelling 2000

Journal: :JNCI Journal of the National Cancer Institute 1998

2010
Christopher Rice L Eric Huang

Angiogenesis has long been recognized as an essential element in tumor growth. Since the conception of antiangiogenesis for cancer therapeutics, great strides have been made in understanding the molecular biology underlying angiogenesis, both in cancer and in physiology. By capitalizing on these advancements through bench-to-bedside research, potent antiangiogenic agents have been developed and...

2008
Li Cun Wu Wei Dong Zhang

Both malignant tumor growth and metastasis are dependent upon angiogenesis, a process of new blood vessel formation. Inhibition of this process by specific inhibitors might be able to control tumor growth and metastasis. Therefore, antiangiogenesis thereapy is considered a promising strategy and being studied worldwide. A wide variety of angiogenesis inhibitors have been identified and some of ...

2010
Domenico Ribatti

Antiangiogenesis, e.g., inhibition of blood vessel growth, is being investigated as a way to prevent the growth of tumors and other angiogenesis-dependent diseases. Pharmacological inhibition interferes with the angiogenic cascade or the immature neovasculature with synthetic or semi-synthetic substances, endogenous inhibitors or biological antagonists.The chick embryo chorioallantoic membrane ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید